Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Endocrine Cancer
ENDOCRINE CANCER ADVISOR
FEATURED CONTENT
-
-
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials. -
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources. -
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes. -
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
ENDOCRINE CANCER NEWS
RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer
FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
Regular Medical Surveillance in World Trade Center Emergency Personnel May Explain Increased Rates of Thyroid Cancer
Aggressive Subtypes of Papillary Thyroid Cancer Deserve Increased Attention
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Endocrine Cancer
